221 related articles for article (PubMed ID: 32224611)
1. Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
Schulze A; Christoph F; Sachs M; Schroeder J; Stephan C; Schostak M; Koenig F
Urol Int; 2020; 104(3-4):181-186. PubMed ID: 32224611
[TBL] [Abstract][Full Text] [Related]
2. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.
Ito K; Miyakubo M; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
World J Urol; 2013 Apr; 31(2):305-11. PubMed ID: 22903772
[TBL] [Abstract][Full Text] [Related]
6. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer.
Boo Y; Chung JH; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Song W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509551
[TBL] [Abstract][Full Text] [Related]
8. The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
Jagarlamudi KK; Zupan M; Kumer K; Fabjan T; Hlebič G; Eriksson S; Osredkar J; Smrkolj T
Prostate; 2019 Jun; 79(8):856-863. PubMed ID: 30889628
[TBL] [Abstract][Full Text] [Related]
9. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.
Chiu ST; Cheng YT; Pu YS; Lu YC; Hong JH; Chung SD; Chiang CH; Huang CY
Front Oncol; 2021; 11():772182. PubMed ID: 34869007
[TBL] [Abstract][Full Text] [Related]
10. PHI density prospectively improves prostate cancer detection.
Stephan C; Jung K; Lein M; Rochow H; Friedersdorff F; Maxeiner A
World J Urol; 2021 Sep; 39(9):3273-3279. PubMed ID: 33471165
[TBL] [Abstract][Full Text] [Related]
11. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
12. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
13. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.
Na R; Ye D; Qi J; Liu F; Helfand BT; Brendler CB; Conran CA; Packiam V; Gong J; Wu Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
Prostate; 2017 Aug; 77(11):1221-1229. PubMed ID: 28664580
[TBL] [Abstract][Full Text] [Related]
14. Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection.
Barisiene M; Bakavicius A; Stanciute D; Jurkeviciene J; Zelvys A; Ulys A; Vitkus D; Jankevicius F
Biomed Res Int; 2020; 2020():9872146. PubMed ID: 32775459
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.
Peters R; Stephan C; Jung K; Lein M; Friedersdorff F; Maxeiner A
Urol Int; 2022; 106(9):878-883. PubMed ID: 34433176
[TBL] [Abstract][Full Text] [Related]
16. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
[TBL] [Abstract][Full Text] [Related]
19. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
[TBL] [Abstract][Full Text] [Related]
20. The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?
Garrido MM; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
Clin Chim Acta; 2021 Sep; 520():133-138. PubMed ID: 34097882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
